{"title":"同种异体干细胞移植中巨细胞病毒选择的血液成分：英国移植中心实践的随访调查。","authors":"Oliver Firth, Suzy Morton","doi":"10.1111/tme.70014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (aSCT). In 2012, the UK Advisory Committee for the Safety of Tissues and Organs (SaBTO) recommended that CMV-unselected (CMV-U) blood components could be safely transfused to this population without increasing the risk of transfusion-transmitted CMV (TTI-CMV). A 2015 survey of UK transplant centres found that 22.7% of aSCT centres did not follow this recommendation. In response, a subsequent good practice paper addressed concerns regarding the determination of pre-transplant CMV serostatus. Annual Serious Hazards of Transfusion (SHOT) reports continue to reassure, with no emerging safety concerns linked to the increased use of CMV-U blood components in this setting.</p><p><strong>Objectives: </strong>To clarify changes in English practice regarding the provision of CMV-U blood components for potential allogeneic stem cell recipients and to identify factors contributing to the continued use of CMV-seronegative (CMV-N) blood components outside SaBTO recommendations.</p><p><strong>Methods: </strong>We surveyed English aSCT centres to establish current practices and perceptions.</p><p><strong>Results: </strong>Of the 32 English transplant centres, 28 responded (88%), 19 adult and nine paediatric centres; 10.7% continue to provide CMV-N components to all CMV-N potential aSCT recipients. Cited reasons include concerns for patients with primary immunodeficiency syndromes and a misperception that TTI-CMV is a 'never event'. Furthermore, 17.9% of centres continue to provide CMV-N components contrary to SaBTO recommendations, citing risks of CMV disease in primary immunodeficiency syndromes, resolution of ambiguous CMV serostatus, and HIV infection.</p><p><strong>Conclusion: </strong>Adherence to SaBTO guidance on transfusion of CMV-U blood components to aSCT recipients continues to improve, but further changes are likely to be challenging, based on the survey responses received and may require international collaboration.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cytomegalovirus-selected blood components in allogeneic stem cell transplantation: A follow-up survey of English transplant centre practices.\",\"authors\":\"Oliver Firth, Suzy Morton\",\"doi\":\"10.1111/tme.70014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (aSCT). In 2012, the UK Advisory Committee for the Safety of Tissues and Organs (SaBTO) recommended that CMV-unselected (CMV-U) blood components could be safely transfused to this population without increasing the risk of transfusion-transmitted CMV (TTI-CMV). A 2015 survey of UK transplant centres found that 22.7% of aSCT centres did not follow this recommendation. In response, a subsequent good practice paper addressed concerns regarding the determination of pre-transplant CMV serostatus. Annual Serious Hazards of Transfusion (SHOT) reports continue to reassure, with no emerging safety concerns linked to the increased use of CMV-U blood components in this setting.</p><p><strong>Objectives: </strong>To clarify changes in English practice regarding the provision of CMV-U blood components for potential allogeneic stem cell recipients and to identify factors contributing to the continued use of CMV-seronegative (CMV-N) blood components outside SaBTO recommendations.</p><p><strong>Methods: </strong>We surveyed English aSCT centres to establish current practices and perceptions.</p><p><strong>Results: </strong>Of the 32 English transplant centres, 28 responded (88%), 19 adult and nine paediatric centres; 10.7% continue to provide CMV-N components to all CMV-N potential aSCT recipients. Cited reasons include concerns for patients with primary immunodeficiency syndromes and a misperception that TTI-CMV is a 'never event'. Furthermore, 17.9% of centres continue to provide CMV-N components contrary to SaBTO recommendations, citing risks of CMV disease in primary immunodeficiency syndromes, resolution of ambiguous CMV serostatus, and HIV infection.</p><p><strong>Conclusion: </strong>Adherence to SaBTO guidance on transfusion of CMV-U blood components to aSCT recipients continues to improve, but further changes are likely to be challenging, based on the survey responses received and may require international collaboration.</p>\",\"PeriodicalId\":23306,\"journal\":{\"name\":\"Transfusion Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transfusion Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/tme.70014\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tme.70014","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Cytomegalovirus-selected blood components in allogeneic stem cell transplantation: A follow-up survey of English transplant centre practices.
Background: Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (aSCT). In 2012, the UK Advisory Committee for the Safety of Tissues and Organs (SaBTO) recommended that CMV-unselected (CMV-U) blood components could be safely transfused to this population without increasing the risk of transfusion-transmitted CMV (TTI-CMV). A 2015 survey of UK transplant centres found that 22.7% of aSCT centres did not follow this recommendation. In response, a subsequent good practice paper addressed concerns regarding the determination of pre-transplant CMV serostatus. Annual Serious Hazards of Transfusion (SHOT) reports continue to reassure, with no emerging safety concerns linked to the increased use of CMV-U blood components in this setting.
Objectives: To clarify changes in English practice regarding the provision of CMV-U blood components for potential allogeneic stem cell recipients and to identify factors contributing to the continued use of CMV-seronegative (CMV-N) blood components outside SaBTO recommendations.
Methods: We surveyed English aSCT centres to establish current practices and perceptions.
Results: Of the 32 English transplant centres, 28 responded (88%), 19 adult and nine paediatric centres; 10.7% continue to provide CMV-N components to all CMV-N potential aSCT recipients. Cited reasons include concerns for patients with primary immunodeficiency syndromes and a misperception that TTI-CMV is a 'never event'. Furthermore, 17.9% of centres continue to provide CMV-N components contrary to SaBTO recommendations, citing risks of CMV disease in primary immunodeficiency syndromes, resolution of ambiguous CMV serostatus, and HIV infection.
Conclusion: Adherence to SaBTO guidance on transfusion of CMV-U blood components to aSCT recipients continues to improve, but further changes are likely to be challenging, based on the survey responses received and may require international collaboration.
期刊介绍：
Transfusion Medicine publishes articles on transfusion medicine in its widest context, including blood transfusion practice (blood procurement, pharmaceutical, clinical, scientific, computing and documentary aspects), immunohaematology, immunogenetics, histocompatibility, medico-legal applications, and related molecular biology and biotechnology.
In addition to original articles, which may include brief communications and case reports, the journal contains a regular educational section (based on invited reviews and state-of-the-art reports), technical section (including quality assurance and current practice guidelines), leading articles, letters to the editor, occasional historical articles and signed book reviews. Some lectures from Society meetings that are likely to be of general interest to readers of the Journal may be published at the discretion of the Editor and subject to the availability of space in the Journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
